BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 33643384)

  • 1. m
    Wang H; Zhao X; Lu Z
    Front Genet; 2021; 12():622233. PubMed ID: 33643384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IGF2BP3 is an essential N
    Xu X; Cui J; Wang H; Ma L; Zhang X; Guo W; Xue X; Wang Y; Qiu S; Tian X; Miao Y; Wu M; Yu Y; Xu Y; Wang J; Qiao Y
    Mater Today Bio; 2022 Dec; 17():100503. PubMed ID: 36457846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N6-Methyladenosine RNA Methylation Regulator-Related Alternative Splicing (AS) Gene Signature Predicts Non-Small Cell Lung Cancer Prognosis.
    Zhao Z; Cai Q; Zhang P; He B; Peng X; Tu G; Peng W; Wang L; Yu F; Wang X
    Front Mol Biosci; 2021; 8():657087. PubMed ID: 34179079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of pathology-specific regulators of m
    Li N; Zhan X
    EPMA J; 2020 Sep; 11(3):485-504. PubMed ID: 32849929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and Prognostic Significance of m6A-Related Genes in Lung Adenocarcinoma.
    Zhang Y; Liu X; Liu L; Li J; Hu Q; Sun R
    Med Sci Monit; 2020 Feb; 26():e919644. PubMed ID: 32086933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New roles of N6-methyladenosine methylation system regulating the occurrence of non-alcoholic fatty liver disease with N6-methyladenosine-modified MYC.
    Cheng W; Li M; Zhang L; Zhou C; Yu S; Peng X; Zhang W; Zhang W
    Front Pharmacol; 2022; 13():973116. PubMed ID: 36120320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated Heterogeneous Nuclear Ribonucleoprotein C Expression Correlates With Poor Prognosis in Patients With Surgically Resected Lung Adenocarcinoma.
    Guo W; Huai Q; Zhang G; Guo L; Song P; Xue X; Tan F; Xue Q; Gao S; He J
    Front Oncol; 2020; 10():598437. PubMed ID: 33569346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Four m6A RNA Methylation Gene Signatures and Their Prognostic Values in Lung Adenocarcinoma.
    Wang Y; Zhao X; Li J; Wang X; Hu W; Zhang X
    Technol Cancer Res Treat; 2022; 21():15330338221085373. PubMed ID: 35343834
    [No Abstract]   [Full Text] [Related]  

  • 9. Diagnostic, progressive and prognostic performance of m
    Zhuang Z; Chen L; Mao Y; Zheng Q; Li H; Huang Y; Hu Z; Jin Y
    Int J Biol Sci; 2020; 16(11):1785-1797. PubMed ID: 32398949
    [No Abstract]   [Full Text] [Related]  

  • 10. Upregulation of M6A Reader HNRNPA2B1 Associated with Poor Prognosis and Tumor Progression in Lung Adenocarcinoma.
    Wang W; Li S
    Recent Pat Anticancer Drug Discov; 2023 Oct; ():. PubMed ID: 37877146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. m6A RNA Methylation Regulators Participate in the Malignant Progression and Have Clinical Prognostic Value in Lung Adenocarcinoma.
    Li F; Wang H; Huang H; Zhang L; Wang D; Wan Y
    Front Genet; 2020; 11():994. PubMed ID: 33193582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RNA-Binding Protein IGF2BP1 Associated With Prognosis and Immunotherapy Response in Lung Adenocarcinoma.
    Liu J; Li Z; Cheang I; Li J; Zhou C
    Front Genet; 2022; 13():777399. PubMed ID: 35154270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RBM15 facilities lung adenocarcinoma cell progression by regulating RASSF8 stability through N6 Methyladenosine modification.
    Ma M; Wang W; Li L; Wang X; Huang Q; Zhou C; Huang Y; Zhao G; Ye L
    Transl Oncol; 2024 Aug; 46():102018. PubMed ID: 38838436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic value of N6-methyladenosine RBM15 regulators in lung adenocarcinoma.
    Ma M; Wang W; Wang B; Yang Y; Huang Y; Zhao G; Ye L
    Cell Mol Biol (Noisy-le-grand); 2022 May; 68(1):130-139. PubMed ID: 35809319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. m
    Hou J; Shan H; Zhang Y; Fan Y; Wu B
    Am J Otolaryngol; 2020; 41(4):102547. PubMed ID: 32474328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene Signature and Identification of Clinical Trait-Related m
    Hou J; Wang Z; Li H; Zhang H; Luo L
    Front Genet; 2020; 11():522. PubMed ID: 32754191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2.
    Chen M; Wei L; Law CT; Tsang FH; Shen J; Cheng CL; Tsang LH; Ho DW; Chiu DK; Lee JM; Wong CC; Ng IO; Wong CM
    Hepatology; 2018 Jun; 67(6):2254-2270. PubMed ID: 29171881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive analysis of m6A regulators prognostic value in prostate cancer.
    Ji G; Huang C; He S; Gong Y; Song G; Li X; Zhou L
    Aging (Albany NY); 2020 Jul; 12(14):14863-14884. PubMed ID: 32710725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of m6A methyltransferase component VIRMA in multiple human cancers (Review).
    Zhu W; Wang JZ; Wei JF; Lu C
    Cancer Cell Int; 2021 Mar; 21(1):172. PubMed ID: 33731118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive analysis of the prognostic impact and immune implication of KIAA1429 in lung adenocarcinoma.
    Guo L; Huai Q; Zhou B; Ying J; Guo W
    Cancer Innov; 2022 Dec; 1(4):328-343. PubMed ID: 38089085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.